Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Disease-Modifying Protein Therapeutic for the Treatment of COPD

Award Number: R43HL149580
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2019
PERIOD OF PERFORMANCE END DATE: 03/31/2021

Group Awards By:

View Award Description

A Disease-Modifying Protein Therapeutic for the Treatment of COPD - Project Summary/Abstract COPD is projected to become the third most common cause of death worldwide, and we currently lack any medical therapies that significantly alter the course of this disease. Our recent work identifies ADAM9 (a disintegin and metalloproteinase domain) as the first proteinase that promotes the three key COPD pulmonary pathologies (emphysema, small airway fibrosis, and airway mucus cell metaplasia) in cigarette smoke-exposed mice. Moreover, ADAM9 expression is robustly increased in lung epithelial cells and macrophages in the lungs of COPD patients, even in early-stage disease. Additionally, Adam9 mediates its activities, in part, by increasing lung inflammation, degrading lung elastin, and shedding epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2) to reduce the survival of alveolar septal cells, and increase the number of activated small airway myofibroblasts. We have developed a protein therapeutic based on a domain of ADAM9 that specifically targets this enzyme's activity to reduce shedding of a number of substrates for ADAM9. We have promising results using this protein in mice acutely exposed to smoke. In Aim 1 we will establish the pharmacokinetics, maximum tolerated dose and dosing regimen for use in the efficacy study. Aim 2 will focus on performing a proof-of-concept six-month cigarette-smoke exposure experiment that will serve to demonstrate satisfactory efficacy of our inhibitor. Successful completion of the aims will advance this protein therapeutic towards the clinic as the first disease-modifying therapy for COPD, with potential to slow the progression of key COPD phenotypes associated with lung function impairment, morbidity and mortality.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $46,563 )
2022	2019	VERRA THERAPEUTICS, LLC	127 ASBURY RD	ITHACA	NY	14882	TOMPKINS	USA	Lung Diseases Research	001	1	12/7/2021	NEW	-$55
2022	2019	VERRA THERAPEUTICS, LLC	127 ASBURY RD	ITHACA	NY	14882	TOMPKINS	USA	Lung Diseases Research	000	1	11/22/2021	NEW	$46,618
														Subtotal = $46,563

Issue Date FY: 2021 ( Subtotal = -$46,618 )
2021	2019	VERRA THERAPEUTICS, LLC	127 ASBURY RD	ITHACA	NY	14882	TOMPKINS	USA	Lung Diseases Research	000	1	9/22/2021	NEW	-$46,618
														Subtotal = -$46,618

Issue Date FY: 2019 ( Subtotal = $391,023 )
2019	2019	VERRA THERAPEUTICS, LLC	127 ASBURY RD	ITHACA	NY	14882	TOMPKINS	USA	Lung Diseases Research	000	1	9/13/2019	NEW	$391,023
														Subtotal = $391,023

Grand Total All Awards = $390,968

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Disease-Modifying Protein Therapeutic for the Treatment of COPD

Award Number: R43HL149580

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2019

PERIOD OF PERFORMANCE END DATE: 03/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer